1 factor holding back GLP-1 adoption, stigma might have been the No
7 Patients with T2DM are frequently overweight or obese, and obesity exacerbates the risk of cardiovascular disease in these patients
Tier 2: advanced alternatives in late-stage development These medications are not yet FDA-approved but have completed or are completing Phase 3 clinical trials
While a single case study cannot prove a clear correlation, it shows that in some individuals, GLP-1s may enhance hair growth instead of hindering it
Using more than one imaging method allowed the team to capture different aspects of brown fat biology rather than relying on a single measure
La patognesis de la DM1 y la DM2 es drsticamente diferente y, por lo tanto, cada tipo tiene diversas etiologas, presentaciones y tratamientos